Ekso Bionics Develops Lightweight Flexible Exoskeleton Technology Expanding Technical & Intellectual Property Leadership
RICHMOND, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an exoskeleton company, today announced that it has completed the development of a lightweight, flexible load carriage exoskeleton prototype named Artemis.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/87efda25-f992-427d-b9bf-65209981c202
The patent-pending prototype weighs a mere 13 pounds and can successfully offload up to three-quarters of payload while also being comfortable to wear. While advancing medical and industrial exoskeleton technology, the company is exploring applying Artemis in their product development pipeline.
“Leveraging our extensive core intellectual property provided an advantage in developing flexible load carriage,” explained Kurt Amundson, senior director of EksoHealth and EksoLabs. “Our industry is already actively exploring the benefits of soft exoskeletons. Recently a team of Harvard engineers published their latest findings1 which show promise. Ekso engineers will be able to further explore how to maximize the advantages of soft exoskeletons thanks to the Artemis prototype.”
The intellectual property from this government-funded project will be added to Ekso Bionics’ industry-leading IP portfolio of nearly 200 international patent cases (granted or pending). In late May, Ekso Bionics was granted a patent for a fail-safe system for exoskeleton joints, marking the company’s 30th U.S. patent.
To learn more, visit www.eksobionics.com and connect with us on LinkedIn, Facebook, Twitter, and YouTube. Additional details regarding Artemis are available in the Ekso Bionics Spring 2017 Company Newsletter: http://eksobionics.com/wp-content/uploads/2017/05/eksoworks-newsletter-spring-2017-EKSO0063GTREVA.pdf.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
1 Science Robotics, 18 Jan 2017: Vol. 2, Issue 2, eaah4416
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Media Contact: Carrie Yamond 917-371-2320 firstname.lastname@example.org
Released June 5, 2017